Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off.Nevertheless, the company's prospects remain positive with its portfolio of therapeutic candidates covering metabolic and endocrine diseases. Progress toward regulatory approval with multiple data readouts expected later this year could be the catalyst for shares to rebound sharply.So, should you buy the dip in Viking Therapeutics now? Here's what you need to know.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool